Analysis of the application value of mesalazine combined with live Bacillus licheniformis in the treatment of ulcerative colitis
美沙拉嗪联合地衣芽孢杆菌活菌在溃疡性结肠炎治疗中的应用价值分析

摘要

目的 分析溃疡性结肠炎治疗中联合应用美沙拉嗪与地衣芽孢杆菌活菌的临床价值。方法 将2023年12月-2024年12月治疗的78例溃疡性结肠炎患者作为研究对象，应用双盲法划分小组，对照组39例（美沙拉嗪治疗），实验组39例（美沙拉嗪+地衣芽孢杆菌活菌治疗）。比较两组的治疗效果。结果 实验组的临床症状评分、炎症指标检测结果、临床疗效以及不良反应发生情况均优于对照组（P＜0.05）。结论 在溃疡性结肠炎患者治疗时，应用美沙拉嗪与地衣芽孢杆菌活菌联合治疗，可改善临床症状和患者的炎症指标，预防或减少不良反应的发生，提高治疗效果。

Abstract

Objective To analyze the clinical value of the combined use of mesalazine and live Bacillus licheniformis in the treatment of ulcerative colitis.
Methods A total of 78 patients with ulcerative colitis treated from December 2023 to December 2024 were selected as the research subjects. The double-blind method was used to divide the groups into control group (mesalazine treatment) and experimental group (mesalazine + live Bacillus licheniformis treatment). The therapeutic effects of the two groups were compared.
Results The clinical symptom scores, inflammatory index test results, clinical efficacy and adverse reactions of the experimental group were better than those of the control group (P < 0.05).
Conclusion   In the treatment of patients with ulcerative colitis, the combined treatment of mesalazine and live Bacillus licheniformis can improve clinical symptoms and inflammatory indicators of patients, prevent or reduce the occurrence of adverse reactions, and improve the therapeutic effect.